Obesity - PeptideBlog

Obesity

Investigational Pipeline

Obesity

Compounds still inside company-run clinical trials for weight loss and metabolic disease. None of these are approved for any use, and none are sold by any vendor, including research-chemical or "research use only" sellers. Everything documented here comes from the developer's own registered trials or from published research.

  • Aleniglipron (GSBR-1290)

    Investigational — not available anywhere This compound is not approved for any use and is not currently sold by any vendor, including research-chemical and RUO (“research use only”) sellers. Evidence for aleniglipron comes from Structure Therapeutics’ own published and presented clinical trial data. As an oral small-molecule drug rather than an injectable peptide, it is ... <a title="Aleniglipron (GSBR-1290)" class="read-more" href="https://peptideblog.net/peptides/aleniglipron/" aria-label="Read more about Aleniglipron (GSBR-1290)">Read more</a>

  • Amycretin

    Amycretin is Novo Nordisk's experimental dual GLP-1/amylin receptor agonist for weight loss and type 2 diabetes, with published phase 1b/2a human data showing up to 22% weight loss. Not approved anywhere; phase 3 trials are planned to begin in 2026.

  • MariTide (Maridebart Cafraglutide)

    Investigational — not available anywhere This compound is not approved for any use and is not currently sold by any vendor, including research-chemical and RUO (“research use only”) sellers. Evidence for MariTide comes from Amgen’s own published and presented clinical trial data, not from independent human trials or vendor sources. Because MariTide is a large ... <a title="Aleniglipron (GSBR-1290)" class="read-more" href="https://peptideblog.net/peptides/aleniglipron/" aria-label="Read more about Aleniglipron (GSBR-1290)">Read more</a>

  • NBIP-1968

    NBIP-1968 is Neurocrine Biosciences' investigational GLP-1/GIP/glucagon triple agonist for obesity, just entering phase 1 single-ascending-dose testing in August 2026. Its differentiator is a planned future combination with NBIP-2118 aimed at preserving lean mass. No efficacy data exists yet; never approved, never sold.

  • Nisotirostide

    Nisotirostide (LY3457263) is Eli Lilly's investigational NPY2 receptor agonist, a PYY analog developed as an add-on to GLP-1 drugs like semaglutide and tirzepatide rather than a standalone treatment. Its most advanced trial measures blood sugar control, not weight loss. Not approved anywhere; never sold.

  • Petrelintide

    Petrelintide (ZP8396) is Zealand Pharma and Roche's investigational amylin analog for weight management, now in phase 3. It posted up to 10.7% weight loss in phase 2 with a near-placebo tolerability profile and almost no vomiting. Not approved anywhere; never sold in any form.

  • UBT251

    UBT251 is a GLP-1/GIP/glucagon triple agonist from China's United Biotechnology, licensed to Novo Nordisk, that posted up to 19.7% weight loss in phase 2 and outperformed semaglutide 1 mg head-to-head on both HbA1c and weight in a separate phase 2 diabetes trial. Not approved anywhere; sources disagree on whether China phase 3 has started.